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 College oAbstract Background: Thyrotoxicois is not uncommonly suspected in many ICU patients. There
are many clinical and laboratory fallacies that may hinder the rapid diagnosis of thyrotoxicosis in
ICU patients especially those presenting with cardiac emergencies.
Aim: First, to estimate the thyrotoxic burden in the ICU. Second, to assess the usefulness of thy-
roid ultrasound in early evaluation of suspected thyroid disease in critically ill patients especially
those with life threatening cardiac emergencies.
Patients and methods: 854 patients admitted in 2 general intensive care units from Jan to Novem-
ber 2011 were evaluated. All patients suspected to have thyrotoxicosis were assessed by thyroid
ultrasound and by measurement of serum levels of Ft3,Ft4,TSH, echocardiography and continuous
ECG monitoring. Radioisotope scanning was done in selected cases.
Results: Out of 854 admitted patients, 113 (13.2%) were suspected to have thyrotoxicosis. Thy-
rotoxicosis was proved in 28 patients (24.7% of suspected cases and 3.3% of all admitted cases):
15% of all suspected cases had Graves’ disease and 9.7% had toxic nodules. Most diagnosed
patients (No: 16, 59.3%) had masked thyrotoxicosis. Seventy-six patients (67.3% of suspected
patients) were admitted as critically ill cardiac patients and presented mainly by cardiac arrhyth-
mias, heart failure, acute chest pain and malignant hypertension and 21 of these patients
(27.6%) were proved to be thyrotoxic.354718; fax: +20 862634496.
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130 O.M. Momtaz et al.Conclusion: Thyrotoxicosis and thyrotoxic cardiac emergencies are not uncommon in the ICU
and should be thoroughly investigated as most cases are clinically masked. Thyroid ultrasound is
a feasible, rapid and accurate bedside diagnostic tool for suspected thyrotoxic emergencies in ICU.
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Hyperthyroidism, second to diabetes, is the second common
endocrinal disorder in the general population. The most com-
mon causes of hyperthyoidism are diffuse toxic goiter (Graves’
disease) (GD) (1%), solitary toxic nodules (STN) (0.1%)
and toxic multinodular goiter (TMG) (0.53%) [1].
Although thyrotoxic emergencies are not common causes
for admission to critical care units, thyrotoxicois is not uncom-
monly suspected and thoroughly searched for in many admit-
ted patients. This is due to many reasons: ﬁrst, the overlap of
thyrotoxic symptoms and signs with many diseases encoun-
tered in critical care patients especially those with severe car-
diac and chest diseases and patients with cardiac neurosis
such as tachycardia, arrhythmias, dyspnea, sweating, weight
loss, nervousness, severe anxiety and panic, staring look, col-
lapsing pulse and hand tremors. Second, thyotoxicosis may
not be clinically manifest (subclinical or masked) especially
in old age and in this situation, if not properly and early diag-
nosed, may aggressively deteriorate many seriously ill patients
like those with malignant arrhythmias, severe heart failure and
acute coronary syndromes [2,3]. Third, some thyrotoxic pa-
tients may be initially clinically presenting with thyotoxic car-
diac complications like atrial ﬁbrillation, ventricular
tachycardia, atrial or ventricular ectopics, thyrotoxic heart
failure with absence, or even not clinically prominent, common
thyrotoxic symptoms [4,5]. Fourth, thyromegaly, which is a
common sign of thyrotoxicosis that is searched for to establish
diagnosis may not be evident in about one half of thyotoxic
patients [1].
In critically ill patients, a ﬁfth conﬂict is added in
diagnosis of thyrotoxicosis especially in mild (usually early)
Graves’ disease and in patients with pretoxic thyroid nod-
ules. This conﬂict is caused by the inconsistent laboratory
ﬁndings of thyroid hormones and TSH due to acute disrup-
tion of the normal steady state of these hormones [6–9].
Another problem in early diagnosis of thyrotoxicosis in
seriously ill patients is added by the delay of assessment
of thyroid hormones in most laboratories for at least one
or two days.
Thyroid ultrasound (US) has been used as an adjunctive
tool to assess different thyroid diseases in specialized centers
and outpatient clinics. This test is rapid, safe, feasible, easily
available and informative in many cases if performed by expert
personnel [10–14]. However, its use in the ICU to diagnose
thyrotoxicosis has not been studied.
Aim of the study
This study aimed to:
(1) Assess the thyrotoxic burden in critically ill patients
admitted in ICU.(2) Evaluate the value of thyroid ultrasound as a rapid and
feasible bedside diagnostic tool in early evaluation of
suspected thyroid disease in critically ill patients espe-
cially those with life threatening cardiac emergencies.
Patients and methods
Patients
We studied 854 patients who had been admitted to the general
intensive care unit of Critical Care Department of El-Fayoum
University Hospital and the intensive care unit of Internal
Medicine Department of El-Minia University Hospital.
Patients selection
In all admitted patients, those suspected to have thyrotoxicosis
were selected and thoroughly studied.
Inclusion criteria. Patient selection was based on
(1) Presence of suspected thyrotoxic symptoms and signs
(palpitations, insomnia, nervouseness, panics, weight
loss, appetite changes, sweating, heat intolerance, anti-
thyroid drug therapy, T4 replacement therapy, past his-
tory of thyroid disease or thyroid operation, presence of
goiter or thyrotoxic eye signs or other suspecting thyro-
toxic symptoms and signs),
(2) Presence of persistent unexplained sinus tachycardia,
or presence of atrial ﬁbrillation, PSVT, atrial or
ventricular premature beats, ventricular tachycardia or
ventricular ﬁbrillation at presentation or during ICU
admission.
All suspected patients were subjected to:
(1) Thorough clinical assessment including history, general
examination including heart, chest, abdominal and neu-
rological examination) and local thyroid examination
using World Health Organization 1960 palpation crite-
ria for determination of goiter: (group 0: thyroid gland
not palpable or visible; IA: thyroid gland is only palpa-
ble but not visible; group IB: thyroid gland is palpable
and visible with neck only in raised position; group II:
thyroid gland is palpable and visible with neck not in
raised position; group III: gross enlargement of the thy-
roid gland) [15]. We opted to use WHO 1960 rather than
WHO 1994 palpation criteria as the earlier was more
descriptive for the clinical size of goiter and hence
would compare better with the detailed ultrasound doc-
umented goiter. Thyroid palpation was done by either
the classic posterior approach or by the alternative
anterior approach. Thyrotoxic cardiac emergencies were
Table 1 Demographic data and main cause of admission of
suspected patients.
Demographic data of
suspected patients (N: 113)
Number and percentage
(related to 113 searched
patients)
Gender:
Males 61 (54%)
History of treatment of thyrotoxicosis:
- On therapy 2 (1.8%)
- Discontinued antithyroid drugs 3 (2.7%)
Main cause of admission:
* Cardiac critical care: 76 (67.3%)
Arrhythmias 51 (45.1%)
Heart failure 15 (13.2%)
Acute chest pain 6 (5.3%)
Malignant hypertension 4 (3.5%)
* Respiratory failure 9 (8%)
* cerebrovascular stroke 8 (7%)
* shock 10 (8.8%)
* acute renal failure 6 (5.3%)
* Diabetic ketoacidosis: (N:4) (3.5%) 4 (3.5%)
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to be caused or compromised by thyrotoxicosis (e.g. car-
diac arrhythmias, heart failure).
(2) Laboratory assessment including FT3, FT4, TSH had
been done on the day of ICU admission and if needed
on the day of discharge and then followed in the outpa-
tient clinic in proved cases. Serum sodium and potas-
sium, arterial blood gases, in addition to all routine
and required investigations according to the patient con-
dition had been done as needed.
(3) Thyroid ultrasound.
(4) Echocardiographic assessment.
(5) Continuous ECG monitoring.
(6) Thyroid scanning with 99Tc in selected cases after
discharge.
Exclusion criteria. Patients with inserted tracheostomy tubes
were excluded due to difﬁculty in procedure of thyroid
ultrasound examination.
Procedure
Thyroid ultrasonography was done using a Toshiba scanner
with a 10 MHZ linear transducer. All patients were examined
with the neck hyperextended and a pillow under the shoulders.
Thyroid volumetry was estimated by summation of both thy-
roid lobe volumes. The volume of each thyroid lobe was calcu-
lated according to the formula of calculation of the volume of
an ellipsoid mass by multiplication of the maximum diameters
of the thyroid lobe (width, depth and length) in centimeters by
the correction factor 0.479 to express the volume in milliliters
[16–18]. Goiter was deﬁned by US if total thyroid volume was
more than 25 ml in males and 18 ml in females) [17,18].
Thyroid echogenicity was assessed as normal (like echoge-
nicity of parotid or submandibular salivary gland), hypoecho-
genic, hyperechogenic, homogenous or heterogenous hyper or
hypoechogenic, or diffusely inhomogenous hypoechogenic
[17,18].
Thyroid nodules (solitary or multinodular) or the postabla-
tive remnant of the nodules were assessed by ultrasound volu-
metry, echogenicity and invasion to surrounding structures.
Regional lymph node assessment had been done by ultrasound
[14].
Statistical methods
Collected data were organized, calculated and tabulated. The
results were expressed in numbers and percentages. For quan-
titative data, the mean and standard deviation (SD) were cal-
culated. Comparison of diagnostic accuracy of US and
clinical suspicion in diagnosis of goiter and thyrotoxicosis
was made by measuring the diagnostic accuracy parameters:
sensitivity, speciﬁcity, positive and negative predictive values,
and overall accuracy.
Results
Demographic data of the patients
We studied 854 patients aged 21–78 years (54.2 + 6.6 years;
mean + SD) who had been admitted in the general intensivecare units of Critical Care Department of El-Fayoum Univer-
sity Hospital and Internal Medicine Department of El-Minia
University Hospital. Of these patients, 113 had been evaluated
for clinically suspected thyrotoxcosis. Patient demographics
and cause of admission are shown in Table 1.
Diagnosis of thyroid disease
Diagnosis of goiter
Goiter was clinically suspected in 61 out of 113 patients sus-
pected to be thyrotoxic (54% of all suspected cases and 1.32%
of all admitted cases ranging from grade IB to grade III accord-
ing to WHO classiﬁcation). Ultrasound thyroid volumetry had
proved presence of goiter (deﬁned as increased total thyroid
volume more than 25 ml in males and 18 ml in females) [17,18]
in 42 (out of 61 patients clinically suspected to have goiter)
(68.9%) [including cases of GD with clinically evident goiter
(12 cases), cases with clinically evident thyroid nodules (8 cases)
and cases of diffuse simple goiter (22 cases)] andwas beneﬁcial in
excluding diagnosis of goiter as an important clue of most thy-
rotoxic states in the other 19 patients (31.1%) (Fig. 1). In the
other 52 patients who had been clinically suspected to have thy-
rotoxicosis without goiter suspicion, goiterwas proved in 8 cases
(5 cases withGDand 3 cases with toxic nodules). Comparison of
diagnostic accuracy parameters of clinical versus ultrasound
assessment of goiter is illustrated in Table 2.
Diagnosis of Graves’ disease
Graves’ disease was proved in 17 cases (15%) (12 females and 5
males) as described by minimal total thyroid volume of 13.5 ml
in naive patients and characteristic echogenicity [17–20]. Twelve
cases (70.5%) had clinically evident goiter (grade IA – III) and 5
cases (29.5%) were classiﬁed grade 0. Thyroid ultrasound exam-
ination showed increased thyroid volume of all cases (ranging
23.3–74.2 ml in females and 26.3–67.4 ml in males) (Table 3) .
Thyroid echogenicity was characteristic and was found as 2
forms: the ﬁrst is diffuse homogenous hypoechogenicity in
(A) (B)
Figure 1 Normal thyroid ultrasound in transverse scanning (A) which shows left lobe as well as rim of the isthmus anterior to the
trachea. Carotid vessels and internal jugular veins are seen inferolateral to the lobe and longitudinal scan (B) with normal echogenicity and
no focal lesion.
Table 2 Comparison of diagnostic accuracy parameters of clinical versus ultrasound assessment of goiter in 61 patients clinically
suspected with goiter (out of 113 studied patients suspected with thyrotoxicosis).
Parameter studied Goiter detected by palpation Goiter detected by US
True positive 42 50
True negative 44 63
False positive 8 0
False negative 19 0
Sensitivity 84% 100%
Speciﬁcity 69.8% 100%
Positive predictive value 68.9% 100%
Negative predictive value 84.6% 100%
Overall accuracy 76.1% 100%
Table 3 Diagnosis of Graves’ disease in suspected thyrotoxic patients as assessed by ultrasound and comparison of the presence of
goiter (in diagnosis of GD) by clinical and ultrasound assessment.
Parameter Number and percentage (in relation of 113
suspected thyrotoxic patients)
Proved cases of Graves’ disease in suspected
thyrotoxic patients (N: 113)
17/113 (15%)
Ultrasound proved Graves’ disease 17/17 (100%)
Clinically evident goiter* 12/17 (70.5%)
Clinically missed goiter** 5/17 (29.5%)
* WHO: IA – III (as clinically assessed by WHO classiﬁcation of goiter).
** WHO: 0 (as clinically assessed by WHO classiﬁcation of goiter) (diagnosed only by ultrasound).
132 O.M. Momtaz et al.both lobes (Fig. 2-A), the second is diffuse hetrogenous hyper-
echogenicity with no deﬁnite, even tinny, nodular lesions
(Fig. 2-B).
In 4 cases suspected for Graves’ disease, thyrotoxicosis was
recurrent after subtotal thyriodectomy and remnant of the thy-
roid gland volumes was estimated by ultrasound and ranged
from 23.3 to 29.3 ml with diffuse hypoechogenicity. Active
GD was ﬁnally conﬁrmed in 3 cases by hormonal assessment
and one case proved to be in remission.
Diagnosis of toxic and pretoxic thyroid nodules (Table 4)
Diagnosis of deﬁnite toxic thyroid nodules was found in 11
cases (9.7%) (7 females and 4 males). Only 8 cases (72.7%)
could be detected clinically (grade IA – II) and 3 cases
(27.3%) were clinically overlooked (grade 0).Eight cases (72.7%) had toxic nodules (deﬁned as increased
Ft3, Ft4, suppressed TSH and increased radiotracer uptake by
the nodule with suppression of extranodular thyroid tissue by
thyroid scintiscan: hot nodules) [21,22] and 3 cases (27.3%)
had pretoxic nodules. These 3 cases had mild increase in Ft3,
ft4, suppressed TSH with increased radiotracer uptake by the
nodule with no suppression of the extranodular thyroid tissue
by thyroid scintiscan: worm nodules [21,22].
Thyroid nodules were solitary in 7 cases (63.6) and multino-
dular in 4 cases (36.4%). Nodule volumes ranged 12.3–35.7 ml
and most of them (N: 10) (90.9%) were hyperechogenic in
character, one case was isoechogenic (9.1%) and 5 cases
(45.5%) had nodules with a peripheral halo (reﬂecting normal
compressed thyroid tissue) (Fig. 3). Nodule volumes ranged
from 12.3 to 35.7 ml.
(A) (B)
Figure 2 Thyroid ultrasound which shows the typical US diagnostic pattern of Graves’ disease with increased total thyroid volume
along with either decreased diffuse hypoechogenic pattern (A) or diffuse heterogenous hyperechogenicity with no deﬁnite, even tiny
nodular lesion (B).
Table 4 Diagnosis of thyroid nodules (solitary and multinodular, toxic and pretoxic) in suspected thyrotoxic patients as detected
clinically and by ultrasound.
Parameter Number and percentage
Toxic and pretoxic thyroid nodules
- All cases 11/113 (9.7%)*
- Toxic cases* 8 (72.7%)*
- pretoxic cases* 3 (27.3%)*
Toxic and pretoxic solitary thyroid nodules 7/11 (63.6%)**
Toxic and pretoxic multinodular goiter 4/11 (36.4%)**
Clinically detected thyroid nodules 8/11 (72.7%)**
Clinically missed nodules 3/11 (27.3%)**
* Percentage in relation to all suspected thyrotoxic patients (113 cases).
** Percentage in relation to all proved cases of thyroid nodules (11 cases).
(A) (B)
Figure 3 Thyroid ultrasound (A) showing a solitary toxic nodule with characteristic hyperechogenicity and area of partially cystic
degenerations. Note the regular smooth outer surface and the average volume of the nodule making it difﬁcult to be detected by palpation.
(B) toxic multinodular goiter with characteristic hyperechogenic nodules with peripheral halos.
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critically ill cardiac patients
Out of the 113 suspected thyrotoxic patients, 76 (67.3% of sus-
pected patients) were admitted as critically ill cardiac patients
and presented mainly by cardiac arrhythmias (N: 51), heart
failure (N: 15), acute chest pain (N: 6) and malignant hyperten-
sion (N: 4). Out of these 76 patients, thyrotoxicosis was proved
in 21 patients (27.6%). In the other suspected patients (N: 37patients; 32.7% of the 113 suspected patients) who were admit-
ted for various clinical critical presentations including respira-
tory failure, cerebrovascular stroke, shock, acute renal failure
and diabetic ketoacidosis, thyrotoxicosis was proved in 7 pa-
tients (18.9%).
In all patients suspected for thyrotoxicosis (N: 113), most of
them had tachyarrhythmias (with one or more forms, includ-
ing life threatening arrhythmias) and some were on antiar-
Table 5 Number and percentage of patients with the type of arrhythmia (in relation to 113 suspected patients) and number and
percentage of proved thyrotoxic patients with this arrhythmia (percentage in relation to number of patients presented with the type of
arrhythmia).
Type of arrhythmia Number and percentage
of patients with the type of
arrhythmia (in relation to 113
suspected patients)
Number and percentage of proved
thyrotoxic patients with this
arrhythmia
Sinus tachycardia 78 (69%) 18/78 (23%)
Nodal tachycardia 5 (4.4%) 1/5 (20%)
AF 12 (10.6%) 3/12 (25%)
MAT 5 (4.4%) 1/5 (20%)
APCs 6 (5.3%) 1/6 (16.6%)
VPCs 10 (8.8.%) 2/10 (20%)
V-tac 5 (4.4%) 1/5 (20%)
VF 3 (2.6%) 1/3 (33.3%)
AF: Atrial ﬁbrillation, MAT: multiﬁcal atrial tachycardia, APCs: atrial premature contractions, VPCs; ventricular premature contractions, V-
tac: ventricular tachycardia, VF: ventriculat ﬁbrillation. MAT, APCs, VPCs, V-tac and VF were mostly combined with sinus tachycardia or AF.
Table 6 Overall diagnosis of thyrotoxicosis and US goiter assessment in ICU.
Parameter Number and percentage
of proved cases
Percentage related
to suspected patients
(N: 113) (%)
Percentage related to
all admitted patients
(N: 854) (%)
Graves’ disease (all patients) 17 (60.7%)* 15 2
Patients with toxic nodules (all patients) 11 (39.3%) 9.7 1.3
All thyrotoxic patients 28 24.7 3.3
Patients with masked thyrotoxicosis 16 (59.3%)* 14.2 1.9
Patients with moderate and prominent thyrotoxicosis 12 (40.7%)* 10.5 1.4
Thyrotoxicosis
- With clinically evident goiter** 20 (71.4%)* 17.7. 2.34
- With clinically missed goiter** 8 (28.6%)* 7.1 0.9
Goiter
All cases** 50 37.2 4.9
- With thyrotoxicosis** 28 (56%)*** 17.7. 2.34
- Without thyrotoxicosis** 22 (44%)*** 19.5 2.56
* Percentage in relation to the 28 proved thyrotoxic cases.
** As assessed by US.
*** Percentage in relation to the 50 proved cases with goiter (42 true positive and 8 false negative cases).
134 O.M. Momtaz et al.rhythmic drugs having negative chronotropic agents and
presented with falsely normal heart rate. Details of different
cardiac arrhythmias of suspected patients and proved thyro-
toxic patients are illustrated in Table 5. In addition, six proved
thyrotoxic patients had heart failure (out of 15 patients with
heart failure clinically suspected for thyrotoxicosis i.e. 40%):
2 of them had rheumatic heart disease, 1 had dilated cardiomy-
opathy, 1 had ischemic cardiomyopathy and 2 patients had no
structural heart disease and diagnosed as thyrotoxic heart
failure). One proved thyrotoxic patient had STEMI (out of 6
clinically suspected thyrotoxic patients with acute chest pain
i.e. 16.6%).
Overall thyrotoxic burden in ICU (Table 6)
In 854 patients admitted in ICU, 113 patients were suspected
to be thyrotoxic (13.2%). Of these 113 patients, 17 had Graves’
disease (15% of suspected patients and 2% of all admitted pa-
tients) and 11 patients had toxic nodules (9.7% of suspectedpatients and 1.3% of all admitted patients). This means that
28 cases (24.7% of suspected patients and 3.3% of all admitted
patients) proved to be thyrotoxic. Masked thyrotoxicosis, in
which the patient had few easily overlooked thyrotoxic symp-
toms and signs, was proved in 16 cases (59.3%) whereas 12
cases (40.7%) had either moderate or marked thyrotoxic man-
ifestations. The stepwise approach in our study for diagnosis
of thyrotoxicosis by clinical examination, US assessment and
ﬁnal laboratory assessment is shown in Fig. 4. Details of over-
all thyrotoxic burden are illustrated in Table 6.
Diagnostic accuracy of US versus clinical assessment in
diagnosis of thyrotoxicosis
Comparison of diagnostic accuracy parameters of clinical ver-
sus ultrasound assessment of thyrotoxicosis in the 113 studied
patients suspected with thyrotoxicosis is shown in Table 7. It
should be mentioned that true and false negative parameters
of clinical assessment of thyrotoxicosis were not assessed as
Figure 4 The stepwise approach for the diagnosis of thyrotoxicosis by clinical examination, US assessment and ﬁnal laboratory
assessment.
Table 7 Comparison of diagnostic accuracy parameters of clinical versus ultrasound assessment of thyrotoxicosis (in 113 studied
patients suspected with thyrotoxicosis).
Parameter studied Thyrotoxicosis detected
clinically
Thyrotoxicosis detected
by US
True positive 28 28
True negative Not assessed 85
False positive 85 0
False negative Not assessed 1
Sensitivity Non-assessable 100%
Speciﬁcity Non-assessable 98.8%
Positive predictive value 24.8% 96.6%
Negative predictive value Non-assessable 100%
Overall accuracy Non-assessable 99.1%
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Hence, sensitivity, speciﬁcity, negative predictive value and
overall accuracy of the clinical evaluation could not be
assessed.Discussion
This study had 2 aims. First, was to assess the thyrotoxic bur-
den in critically ill patients admitted in ICU. The second was to
assess the role of thyroid ultrasound as a rapid and feasible
bedside diagnostic tool in accurate and early evaluation of sus-
pected thyroid disease in critically ill patients especially those
with life threatening cardiac emergencies.
Initially, it is to be mentioned that diagnosis of thyrotoxico-
sis is a constellation of clinical, laboratory and thyroid imaging
parameters (ultrasound and radioisotope scanning) which are
all complementary to each others. Whereas the clinical and
laboratory parameters have many fallacies especially in the
ICU and the thyroid radioisotope scanning is not readily
performed in the ICU in addition to its known diagnosticlimitations, the value of thyroid US in bedside diagnosis of
thyrotoxicosis in emergency situations should be emphasized.
To our knowledge, this is the ﬁrst study to assess the feasibility
of thyroid US in the diagnosis of thyrotoxicosis in emergency
settings.
It was very important to evaluate the global burden of thy-
rotoxic presentation and complications in the general ICU.
This was of great importance to avoid overestimation or
underdiagnosis of thyroid diseases especially in the common
conﬂicting issue of the euthyroid sick syndrome encountered
in ICU. Clinical and laboratory difﬁculties commonly encoun-
tered in urgent diagnosis of thyrotoxicosis in critically ill pa-
tients created a need to search for a rapid, feasible and
accurate bedside tool to conﬁrm or exclude the diagnosis
and hence to allow early and proper management of thyrotox-
icosis and its life threatening co-morbid conditions especially
in hemodynamically unstable patients.
Thyrotoxic burden in the general ICU in our study was
found in 3.3% of all admitted patients. GD was encountered
in 2% and toxic nodules represented 1.3% of admitted pa-
tients. Final diagnosis of thyrotoxicosis was proved in 24.7%
136 O.M. Momtaz et al.of suspected cases, of whom 59.3% had masked thyrotoxic
symptoms and signs and could be easily overlooked. In a pre-
vious study of prevalence of thyroid disease in 2805 attendants
of the outpatient clinic of Internal Medicine Department in El-
Minia University Hospital, 1.06% had GD and 0.64% had
toxic nodules [23]. Thus, thyrotoxic burden in the ICU was
found to be about double the burden encountered in the out-
patient clinic which also came hand in hand by most reports
concerning prevalence of thyrotoxicosis in the general
population [24]. This may reﬂect the impact of thyroid dys-
function on co-morbid conditions mandating ICU admission,
and/or the impact of co-morbidity on unmasking or aggravat-
ing thyrotoxicosis.
It was well noted that most of our patients (67.3%) with
suspected thyrotoxicosis had cardiac problems especially car-
diac arrhythmias (45.1%). These ﬁndings highlighted the in-
creased occurrence of thyrotoxicosis among patients with
various tachyarrhythmias and emphasize meticulous search
for thyrotoxicosis in such patients.
Data concerning the precise incidence of different tachyar-
rhythmias in thyrotoxic patients are lacking except for sinus
tachycardia which occurs in nearly all patients (except for pa-
tients taking agents with negative chronotropic effect and case
reports of severe thyrotoxicosis presented with complete heart
block) and AF which occurs in 5–15% of thyrotoxic patients
as reported by different population studies [25]. In this study,
AF was found to occur in a higher percentage than reported by
different studies. The higher incidence of AF may be attributed
to the type of patients in our study, the thyrotoxic critically ill
patients, who may have additional contributing factors for the
development of AF than patients with mere thyrotoxicosis.
However, further large sampled study may be needed to eval-
uate the relation of thyrotoxicosis with other types of tachyar-
rhythmias found in our study.
Thyroid ultrasound had been used as an adjunctive tool to
assess different thyroid diseases in specialized centers and out-
patient clinics. However, its use in the ICU patients for rapid
or complementary assessment of thyrotoxic emergencies had
not been previously studied.
Thyroid ultrasound had proved to be beneﬁcial in diagnosis
of goiter. Goiter is deﬁned as thyroid enlargement of more
than 18 ml in females and 25 ml in males [17,18]. Goiter per
se is an important clinical clue in diagnosis of most cases of
thyroxicosis. Assessment of thyroid volumetry by bedside thy-
roid US was an invaluable tool in conﬁrmation and exclusion
of the fallacious palpation of goiter in our study (31.1% falsely
felt and 29.5% and 27.3% missed goiter and nodule, respec-
tively). However, it should be noted that clinical palpation of
the thyroid may have been inaccurate in recumbent, especially
intubated patients.
Echogenicity of the thyroid gland by US, along with in-
creased thyroid volume, could instantly and correctly diagnose
patients with previously undiagnosed or diagnosed but remit-
ted GD, as well as those with recurrent GD after medical or
ablative therapy. Thyroid volume greater than 16.5 ml is essen-
tial to diagnose GD in naive patients (GD in activity and not
under treatment). In all patients with active GD, thyroid US
showed either diffuse homogenous hypoechogenicity or diffuse
hetergenicity with no deﬁnite nodular lesion.
One important issue that could create confusion is that
about 30% of patients of old remittent cases of GD retain
the same US image of diffuse hypoechogenicity for many yearsand subsequently resembling the US image of active GD. In
such a case, the clinical presentation and hormonal assay of
thyrotoxicosis would solve the dilemma. In our study, we
had 4 cases suspected to have recurrence of GD; 3 cases sus-
pected to have postoperative recurrence and one case sus-
pected to have relapse of the disease. In these suspected
cases, presence of GD per se, whether recent, recurrent or inac-
tive had been conﬁrmed by US (increased thyroid volume and
characteristic thyroid echogenicity). This ultrasound picture
along with presence of clinical thyrotoxic manifestations
pointed to activity rather than remission of GD. However, 3
of those critically ill cases were hemodynamically unstable
and the immediate clinically-based decision for intiating ther-
apy was imperative while laboratory results were still pending.
Antithyroid drugs were initiated considering the fact that thy-
rotoxic consequences in a critically ill patient are more precar-
ious than the undue antithyroid therapy for a limited duration
(2 days). Final diagnosis of GD activity (by thyroid hormone
assay) was conﬁrmed in 3 cases and disproved in one case.
Diagnosis of thyroid nodules (solitary and multiple) was
perfectly conﬁrmed by US. Three out of 11 patients had been
clinically overlooked (27.3%) (grade 0) due to obesity and
short neck. As shown in previous studies, solitary toxic nodule
is usually slowly progressive in size and toxicity merging from
pretoxic to toxic state and usually becomes toxic when
attaining a diameter of about 2.5 cm [21,22]. Most toxic nod-
ules in this study were hyperechogenic and some had periphe-
ral halo expressing normal compressed thyroid tissue. Nodule
volumes attained a size of 12.3–35.7 ml and toxicity was more
prevalent in larger sized nodules. Small sized nodules were
mostly pretoxic as proved later by radioisotope study.
Proper diagnosis of toxic thyroid nodules not only allowed
early management of thyrotoxicosis in cardiac arrhythmias but
also helped in precluding drugs with potentially deleterious ef-
fects such as amiodarone. Amiodarone is commonly used in
treatment of supraventricular and ventricular arrhythmias
and may induce thyrotoxicosis in patients with thyroid nodules
even if the nodule is nontoxic as it is an iodine containing drug.
It also increases toxicity of GD. This actually occurred in one
interesting case in our study who had been referred to ICU
with ventricular tachycardia which was described to be refrac-
tory to treatment with amiodarone given intravenously in a
loading dose and later showed more deterioration of ventricu-
lar tachycardia with the addition of IV maintenance dose of
amiodarone in the following 12 h. Thyroid nodule was not de-
tected clinically in this case as the patient was obese and had a
short neck. By US examination, a solitary hyperechogenic thy-
roid nodule. 2.7 cm in diameter was detected. This might
explain refractoriness and deterioration of ventricular tachy-
cardia as amiodarone was alleged to induce toxicity if the
nodule was nontoxic and to cause more toxicity if the nodule
was toxic. Amiodarone treatment was stopped and propylthy-
rouracil and propranolol were given before thyroid hormone
assessment. Ft3 and Ft4 were assessed and were found to be
markedly increased and TSH was normal indicating recent
rather than old thyrotoxicosis as TSH takes a long time to
be suppressed in response to excess thyroid hormones. Thus
in this patient, amiodarone had induced toxicity in a previ-
ously present nontoxic thyroid nodule.
Thyroid US helped in proper and early diagnosis of thyro-
toxicosis in seriously ill patients who had moderate and prom-
inent thyrotoxic symptoms (40.7% of diagnosed patients)
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before waiting for laboratory diagnosis. This beneﬁt was
clearly manifest in the case of STEMI, malignant arrhythmias
and refractory heart failure.
Thyroid ultrasound was beneﬁcial in proper and early diag-
nosis of thyrotoxicosis in critically ill hemodynamically unsta-
ble patients who had no prominent thyrotoxic symptoms
(masked thyrotoxicosis). This was represented in 59.3% of
all diagnosed thyrotoxic patients in ICU. This high percentage
of presentation of masked thyotoxicosis in ICU reﬂects the
overlap of clinical picture of thyrotoxicosis with variable signs
and symptoms commonly encountered in critically ill patients
such as tachyarrhythmias, dyspnea, insomnia, weight loss,
anxiety, panics, sweating, hand tremors and staring. Second,
masked thyrotoxicosis is commonly encountered in older aged
group who represented most of the admitted patients in our
study and in most intensive care units. Third, subclinical thy-
rotoxicosis, although not easily diagnosed clinically in a
healthy individual in the outpatient clinic, results in signiﬁcant
manifestation in a critically ill patient with other co-morbid
serious conditions, and hence can be commonly encountered
and should be searched for in the ICU. Fourth, thyromegaly
was not prominent clinically in 29.5% of patients with GD
and in 27.3% in toxic nodules and diagnosed perfectly by US.
The overall accuracy of US in diagnosis of thyrotoxicosis
was assessed and compared to clinical assessment and both
measures (clinical and US) were evaluated in relation to ﬁnal
diagnosis of thyrotoxicosis by hormonal proﬁle in all suspected
patients and radioisotope scanning in selected cases. The sen-
sitivity of thyroid US in diagnosis of thyrotoxicosis was
100%, sensitivity 98.8%, negative predictive value 100% and
overall accuracy 96.5% compared to a positive predictive value
of 24.8% for clinical assessment addressing the invaluable
diagnostic role of US. On the other hand, diagnosis of goiter
per se by clinical examination had a sensitivity 84%, speciﬁcity
69.8%, positive predictive value 68.9%, negative predictive
value 84.6% and overall accuracy 76.1% compared to 100%
for all these accuracy parameters of US emphasizing the role
of US as the gold standard for the diagnosis of goiter.
Study limitations
There are three limitations that need to be acknowledged and
addressed regarding the present study. The ﬁrst limitation con-
cerned thyroid palpation in critically ill that could have been
imprecise as there might be inter-observer variability but we
tried to limit the number of examining physicians by only 3
examiners. The second limitation concerned thyroid palpation
in lying position that could have limited the accuracy of palpa-
tion especially in intubated patients; however, this was only
found in 9 patients. The third limitation was that the authors
could not assess the sensitivity of clinical examination, nor
the euthyroid sick state, since the design of the study was only
to perform US and hormone assay for suspected cases rather
than all admitted cases.
In conclusion, thyrotoxicosis is commonly encountered in
the ICU and masked cases should be thoroughly searched
for especially in cardiac patients. Bedside US is an invaluable
tool in early, rapid and accurate diagnosis of thyrotoxicosis
and thyrotoxic emergencies.References
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